- Home
- CAN vs AVIR Comparison
CAN vs AVIR Comparison
Compare CAN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- AVIR
- Stock Information
- Founded
- CAN 2013
- AVIR 2012
- Country
- CAN Singapore
- AVIR United States
- Employees
- CAN N/A
- AVIR N/A
- Industry
- CAN Semiconductors
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- CAN Technology
- AVIR Health Care
- Exchange
- CAN Nasdaq
- AVIR Nasdaq
- Market Cap
- CAN 384.3M
- AVIR 273.0M
- IPO Year
- CAN 2019
- AVIR 2020
- Fundamental
- Price
- CAN $0.71
- AVIR $3.74
- Analyst Decision
- CAN Strong Buy
- AVIR Hold
- Analyst Count
- CAN 6
- AVIR 1
- Target Price
- CAN $2.67
- AVIR $6.00
- AVG Volume (30 Days)
- CAN 28.9M
- AVIR 413.9K
- Earning Date
- CAN 08-14-2025
- AVIR 08-06-2025
- Dividend Yield
- CAN N/A
- AVIR N/A
- EPS Growth
- CAN N/A
- AVIR N/A
- EPS
- CAN N/A
- AVIR N/A
- Revenue
- CAN $317,009,000.00
- AVIR N/A
- Revenue This Year
- CAN $160.28
- AVIR N/A
- Revenue Next Year
- CAN $35.68
- AVIR N/A
- P/E Ratio
- CAN N/A
- AVIR N/A
- Revenue Growth
- CAN 65.68
- AVIR N/A
- 52 Week Low
- CAN $0.53
- AVIR $2.46
- 52 Week High
- CAN $3.27
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- CAN 53.84
- AVIR 75.75
- Support Level
- CAN $0.58
- AVIR $3.43
- Resistance Level
- CAN $0.62
- AVIR $3.80
- Average True Range (ATR)
- CAN 0.05
- AVIR 0.14
- MACD
- CAN 0.01
- AVIR 0.03
- Stochastic Oscillator
- CAN 75.53
- AVIR 78.46
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).